Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C

OBJECTIVE: The treatment of the chronic hepatitis C (HCV) with α-interferon is associated with thyroid dysfunction (TD). The aim of this study was to evaluate thyroid function outcome among patients with chronic HCV under treatment with conventional interferon (IFN) or peguilated interferon (PEG-IFN) in association with ribavirin. PATIENTS AND METHODS: We studied 293 patients with chronic HCV, submitted to drug therapy for 24 or 48 weeks. Initially, we evaluated FT4, TSH, TPOAb, TgAb, and continued to monitor FT4 and TSH every three months during therapy and six months thereafter. RESULTS: At baseline, TD prevalence was 6.82% (n = 20); 6.14% hypothyroidism; 0.68% hyperthyroidism. TPOAb was present in 5.46% of euthyroid patients. Out of 273 euthyroid patients at baseline, 19% developed TD: 17.2% hypothyroidism; 1.8% hyperthyroidism; 5.1% destructive thyroiditis (DT). 90% of TPOAb-positive patients at baseline developed hypothyroidism vs 14.5% of TPOAb-negative patients (p < 0.001). On average, TD occurred after 25.8 ± 15.5 weeks of treatment. 87.2% of patients who developed hypothyroidism did so during the first therapeutic cycle (p = 0.004; OR = 3.52; 95% CI = 1.36-9.65). Patients infected with genotype 1 virus were 2.13 times more likely to develop hypothyroidism (p = 0.036; 95% CI = 1.04-4.38). Hypothyroid and DT patients presented higher TSH levels before-treatment than patients who had remained euthyroid (p < 0.001; p = 0.002, respectively). DT patients presented lower qALT (p = 0.012) than euthyroid patients. CONCLUSION: Hypothyroidism was the most frequent TD, especially during the first cycle of α-interferon. Genotype 1 virus was associated with a risk two times higher for developing the illness. There was no need to interrupt or to change HCV treatment. Therefore, approximately 34% of TD was transient.

Saved in:
Bibliographic Details
Main Authors: Pavan,Maria Helena Postal, Pavin,Elizabeth João, Gonçales Jr,Fernando Lopes, Zantut-Wittmann,Denise Engelbrecht
Format: Digital revista
Language:English
Published: Brazilian Society of Infectious Diseases 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000500006
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1413-86702011000500006
record_format ojs
spelling oai:scielo:S1413-867020110005000062013-02-20Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis CPavan,Maria Helena PostalPavin,Elizabeth JoãoGonçales Jr,Fernando LopesZantut-Wittmann,Denise Engelbrecht hypothyroidism hepatitis C, chronic interferon-α OBJECTIVE: The treatment of the chronic hepatitis C (HCV) with α-interferon is associated with thyroid dysfunction (TD). The aim of this study was to evaluate thyroid function outcome among patients with chronic HCV under treatment with conventional interferon (IFN) or peguilated interferon (PEG-IFN) in association with ribavirin. PATIENTS AND METHODS: We studied 293 patients with chronic HCV, submitted to drug therapy for 24 or 48 weeks. Initially, we evaluated FT4, TSH, TPOAb, TgAb, and continued to monitor FT4 and TSH every three months during therapy and six months thereafter. RESULTS: At baseline, TD prevalence was 6.82% (n = 20); 6.14% hypothyroidism; 0.68% hyperthyroidism. TPOAb was present in 5.46% of euthyroid patients. Out of 273 euthyroid patients at baseline, 19% developed TD: 17.2% hypothyroidism; 1.8% hyperthyroidism; 5.1% destructive thyroiditis (DT). 90% of TPOAb-positive patients at baseline developed hypothyroidism vs 14.5% of TPOAb-negative patients (p < 0.001). On average, TD occurred after 25.8 ± 15.5 weeks of treatment. 87.2% of patients who developed hypothyroidism did so during the first therapeutic cycle (p = 0.004; OR = 3.52; 95% CI = 1.36-9.65). Patients infected with genotype 1 virus were 2.13 times more likely to develop hypothyroidism (p = 0.036; 95% CI = 1.04-4.38). Hypothyroid and DT patients presented higher TSH levels before-treatment than patients who had remained euthyroid (p < 0.001; p = 0.002, respectively). DT patients presented lower qALT (p = 0.012) than euthyroid patients. CONCLUSION: Hypothyroidism was the most frequent TD, especially during the first cycle of α-interferon. Genotype 1 virus was associated with a risk two times higher for developing the illness. There was no need to interrupt or to change HCV treatment. Therefore, approximately 34% of TD was transient.info:eu-repo/semantics/openAccessBrazilian Society of Infectious DiseasesBrazilian Journal of Infectious Diseases v.15 n.5 20112011-10-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000500006en10.1590/S1413-86702011000500006
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Pavan,Maria Helena Postal
Pavin,Elizabeth João
Gonçales Jr,Fernando Lopes
Zantut-Wittmann,Denise Engelbrecht
spellingShingle Pavan,Maria Helena Postal
Pavin,Elizabeth João
Gonçales Jr,Fernando Lopes
Zantut-Wittmann,Denise Engelbrecht
Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C
author_facet Pavan,Maria Helena Postal
Pavin,Elizabeth João
Gonçales Jr,Fernando Lopes
Zantut-Wittmann,Denise Engelbrecht
author_sort Pavan,Maria Helena Postal
title Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C
title_short Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C
title_full Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C
title_fullStr Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C
title_full_unstemmed Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C
title_sort virus c genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis c
description OBJECTIVE: The treatment of the chronic hepatitis C (HCV) with α-interferon is associated with thyroid dysfunction (TD). The aim of this study was to evaluate thyroid function outcome among patients with chronic HCV under treatment with conventional interferon (IFN) or peguilated interferon (PEG-IFN) in association with ribavirin. PATIENTS AND METHODS: We studied 293 patients with chronic HCV, submitted to drug therapy for 24 or 48 weeks. Initially, we evaluated FT4, TSH, TPOAb, TgAb, and continued to monitor FT4 and TSH every three months during therapy and six months thereafter. RESULTS: At baseline, TD prevalence was 6.82% (n = 20); 6.14% hypothyroidism; 0.68% hyperthyroidism. TPOAb was present in 5.46% of euthyroid patients. Out of 273 euthyroid patients at baseline, 19% developed TD: 17.2% hypothyroidism; 1.8% hyperthyroidism; 5.1% destructive thyroiditis (DT). 90% of TPOAb-positive patients at baseline developed hypothyroidism vs 14.5% of TPOAb-negative patients (p < 0.001). On average, TD occurred after 25.8 ± 15.5 weeks of treatment. 87.2% of patients who developed hypothyroidism did so during the first therapeutic cycle (p = 0.004; OR = 3.52; 95% CI = 1.36-9.65). Patients infected with genotype 1 virus were 2.13 times more likely to develop hypothyroidism (p = 0.036; 95% CI = 1.04-4.38). Hypothyroid and DT patients presented higher TSH levels before-treatment than patients who had remained euthyroid (p < 0.001; p = 0.002, respectively). DT patients presented lower qALT (p = 0.012) than euthyroid patients. CONCLUSION: Hypothyroidism was the most frequent TD, especially during the first cycle of α-interferon. Genotype 1 virus was associated with a risk two times higher for developing the illness. There was no need to interrupt or to change HCV treatment. Therefore, approximately 34% of TD was transient.
publisher Brazilian Society of Infectious Diseases
publishDate 2011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000500006
work_keys_str_mv AT pavanmariahelenapostal viruscgenotypepredisposestoprimaryhypothyroidismduringinterferonatreatmentforchronichepatitisc
AT pavinelizabethjoao viruscgenotypepredisposestoprimaryhypothyroidismduringinterferonatreatmentforchronichepatitisc
AT goncalesjrfernandolopes viruscgenotypepredisposestoprimaryhypothyroidismduringinterferonatreatmentforchronichepatitisc
AT zantutwittmanndeniseengelbrecht viruscgenotypepredisposestoprimaryhypothyroidismduringinterferonatreatmentforchronichepatitisc
_version_ 1756416433658527744